Investigation of ANG II/AT1 Receptors with PET

用 PET 研究 ANG II/AT1 受体

• 批准号: 7651405
• 负责人: ZSOLT SZABO
• 金额: $ 34.64万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7651405
• 关键词: ANG gene; Accounting; Acute; Address; Affect; Affinity; Algorithms; Angiotensin II; Angiotensin Receptor; Animal Model; Animals; Applications Grants; Arts; Atherosclerosis; Autoradiography; Behavior; Binding; Binding Sites; Biologic Characteristic; Biological Markers; Blood flow; Canis familiaris; Characteristics; Clip; Collimator; Computational algorithm; Data; Deterioration; Diabetes Mellitus; Diagnosis; Dietary Sodium; Digestive System Disorders; Disease; Estrogens; Failure; Family suidae; Financial compensation; Funding; Future; Goals; Grant; Human; Hypertension; Image; Imaging Device; Imaging Techniques; In Vitro; Investigation; Kidney; Kidney Diseases; Kidney Part; Kinetics; Lead; Link; Measures; Metabolic syndrome; Methods; Modeling; Molecular; Molecular Diagnosis; Monitor; Motion; NIH Program Announcements; Obesity; Organ; Patient Selection; Perfusion; Persons; Pharmaceutical Preparations; Pharmacotherapy; Photons; Positioning Attribute; Positron; Positron-Emission Tomography; Predisposition; Process; Property; Public Health; Recovery; Recurrence; Regulation; Renal Artery Stenosis; Renal Blood Flow; Reperfusion Therapy; Research; Staging; Stenosis; System; Technology; Testing; Time; Translations; Up-Regulation; Variant; attenuation; clinical application; clinical practice; density; design; detector; image processing; image reconstruction; improved; in vivo; instrument; kidney vascular structure; minimally invasive; molecular imaging; novel; pre-clinical; public health relevance; radioligand; receptor; receptor binding; receptor expression; research study; response; restoration; success; uptake; urologic

DESCRIPTION (provided by applicant): During the previous funding period of this grant, several radioligands were synthesized for positron emission tomography (PET) imaging of the angiotensin II/subtype 1 receptor (AT1R). The effects of dietary sodium, estrogen, various drugs and arterial stenosis on radioligand binding in the kidneys were investigated. The results of these experiments reinforced the soundness of positron emission tomography (PET) as a state-of-the-art noninvasive imaging technique for studying the regulation of renal AT1R in vivo. Although the ultimate goal is to apply this molecular imaging tool in humans, kinetic properties of the radioligands need first be clarified in animal models. Our initial observations in dogs and pigs showed increased binding of the radioligand in renal artery stenosis. The important task remaining is to understand and quantify the distribution and kinetics of the PET radioligand in response to altered renal blood flow. To accomplish this, PET studies are proposed in dogs with and without reduced perfusion of the kidneys. The following specific aims will be addressed: Aim 1: To determine to what degree radioligand binding parameters obtained with PET studies are affected by renal blood flow. Experiments are proposed to test the hypothesis that increased in vivo radioligand binding observed in vivo correlates with in vitro quantification of the receptor in Goldblatt models of renal hypoperfusion. We also postulate that after restoration of blood flow radioligand binding will return to pre-ischemic levels. Aim 2: To apply novel quantitative PET image reconstruction and post-processing algorithms for improved receptor quantification in vivo. This aim will address the hypothesis that computational compensation for image degradation and radioligand delivery can provide receptor binding parameters largely independent of global and regional variations of organ perfusion. Integration of the preclinical experiments and the novel computational algorithms will facilitate translation of renal molecular imaging into clinical practice and lead to a rational approach for molecular diagnosis of renovascular disease. PUBLIC HEALTH RELEVANCE Kidney disease remains an important public health problem since it is closely linked to obesity, metabolic syndrome, diabetes, atherosclerosis and hypertension. The imaging techniques currently used to evaluate involvement of the kidneys rely on anatomical data. In contrast, positron emission tomography imaging (PET) makes it possible to study diseases at the molecular level. The proposed research is designed to establish PET imaging of the angiotensin receptor. In the future, this new molecular imaging tool is expected to diagnose kidney disease sooner, guide therapy, measure therapy response and detect disease recurrence or deterioration at an earlier stage.

描述（由申请人提供）：在本资助的前一个资助期间，合成了几种放射性配体，用于血管紧张素II/亚型1受体（AT1R）的正电子发射断层扫描（PET）成像。研究了膳食钠、雌激素、各种药物和动脉狭窄对肾内放射性配体结合的影响。这些实验的结果加强了正电子发射断层扫描（PET）作为研究体内肾脏AT1R调节的最先进的无创成像技术的合理性。尽管最终目标是将这种分子成像工具应用于人类，但放射性配体的动力学特性需要首先在动物模型中得到澄清。我们对狗和猪的初步观察显示，肾动脉狭窄中放射配体的结合增加。接下来的重要任务是了解和量化PET放射配体在肾血流改变时的分布和动力学。为了实现这一点，PET研究建议在肾脏灌注减少和不减少的狗身上进行。目的1：确定PET研究获得的放射配体结合参数在多大程度上受到肾血流的影响。在Goldblatt肾低灌注模型中，体内观察到的放射配体结合增加与受体的体外定量相关，提出了实验来验证这一假设。我们还假设，血流恢复后，放射性配体结合将恢复到缺血前的水平。目的2：应用新的定量PET图像重建和后处理算法来改进体内受体定量。这一目标将解决这样一个假设，即图像退化和放射配体递送的计算补偿可以提供受体结合参数，这在很大程度上独立于器官灌注的整体和区域变化。将临床前实验和新的计算算法相结合，将有助于肾脏分子成像转化为临床实践，并为肾脏血管疾病的分子诊断提供合理的方法。肾脏疾病仍然是一个重要的公共卫生问题，因为它与肥胖、代谢综合征、糖尿病、动脉粥样硬化和高血压密切相关。目前用于评估肾脏受累的成像技术依赖于解剖学数据。相反，正电子发射断层扫描成像（PET）使得在分子水平上研究疾病成为可能。本研究旨在建立血管紧张素受体的PET成像。在未来，这种新的分子成像工具有望更快地诊断肾脏疾病，指导治疗，测量治疗反应，并在早期发现疾病复发或恶化。